Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) generates frequent news as a commercial-stage biopharmaceutical company focused on rare diseases, particularly rare blood disorders. Company updates often center on clinical trial results, regulatory decisions, commercial launches, and financial performance related to its portfolio of small-molecule therapies such as mitapivat.
Readers following AGIO news can expect detailed coverage of developments in the PK activation franchise, including mitapivat in thalassemia, sickle cell disease, and pyruvate kinase (PK) deficiency. Recent announcements have highlighted U.S. Food and Drug Administration (FDA) approval of AQVESME (mitapivat) for anemia in adults with alpha- or beta-thalassemia, positive CHMP opinions in Europe for PYRUKYND (mitapivat) in thalassemia, and topline results from the RISE UP Phase 3 trial in sickle cell disease.
News items also include financial results, such as quarterly revenue from PYRUKYND, updates on cash and investment balances, and commentary on research and development spending. Corporate communications frequently discuss anticipated milestones for ongoing trials of tebapivat, AG-236, and AG-181, as well as strategic priorities to advance Agios’ rare disease portfolio.
Investors and observers can use this page to track AGIO press releases on regulatory interactions, Risk Evaluation and Mitigation Strategy (REMS) implementation for AQVESME, partnerships for commercialization in Europe and the Middle East, and presentations at major medical and investor conferences. Bookmark this news feed to monitor how clinical data, approvals, and commercial execution shape the outlook for Agios Pharmaceuticals within the rare disease and hematology landscape.
Agios Pharmaceuticals (NASDAQ: AGIO) will hold a conference call on November 3, 2021, at 8:00 a.m. ET to discuss its third quarter 2021 financial results. The call will be accessible by phone and via a live webcast on Agios' website. The company is focused on developing medicines for genetically defined diseases, with its lead candidate, mitapivat, being evaluated for three distinct hemolytic anemias. A replay of the event will be available shortly after the conclusion.
Agios Pharmaceuticals (NASDAQ: AGIO) announced its participation in two upcoming investor conferences. The Citi’s 16th Annual Biopharma Virtual Conference will feature a panel on Sickle Cell and related conditions on September 10 at 12:30 p.m. ET. Additionally, the 2021 Cantor Virtual Global Healthcare Conference is scheduled for September 27 at 8:00 a.m. ET. Live webcasts will be available on their website, with replays accessible for at least two weeks post-event. Agios focuses on innovative treatments for genetically defined diseases, with its leading drug candidate, mitapivat, targeting hemolytic anemias.
Agios Pharmaceuticals announced on August 17, 2021, that the FDA has accepted its New Drug Application (NDA) for mitapivat, aimed at treating adults with pyruvate kinase deficiency. This NDA received a Priority Review designation, expediting the review process to a PDUFA date of February 17, 2022. Mitapivat is being positioned as a potential first disease-modifying therapy for this chronic condition, with the FDA’s designation indicating significant improvements in treatment.
Agios Pharmaceuticals (AGIO) recently completed regulatory submissions for mitapivat, targeting adults with Pyruvate Kinase deficiency in the U.S. and EU. The company presented positive Phase 3 study results for mitapivat at the EHA Virtual Congress, showing strong efficacy, including an 80% hemoglobin increase in thalassemia patients. Q2 2021 R&D expenses rose to $62 million, while net loss decreased to $86.2 million. Agios reported $1.7 billion in cash reserves, sufficient for ongoing operations and future developments, including two planned Phase 3 trials and a Phase 2/3 trial in sickle cell disease.
Agios Pharmaceuticals (NASDAQ: AGIO) has scheduled a conference call for July 29, 2021, at 8:00 a.m. ET to discuss its second quarter 2021 financial results and business highlights. The call will be accessible via telephone or live webcast through the company’s website. Agios specializes in developing medicines for genetically defined diseases, with its lead drug candidate, mitapivat, targeting hemolytic anemias.
Agios Pharmaceuticals (NASDAQ: AGIO) has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for mitapivat, aimed at treating adults with pyruvate kinase deficiency. This follows a recent New Drug Application (NDA) to the FDA. Mitapivat is designed to offer a first-in-class therapy for this chronic hemolytic anemia, characterized by serious complications and no approved treatments currently available. The application is backed by pivotal study results and ongoing studies to evaluate long-term efficacy.
Agios Pharmaceuticals (NASDAQ: AGIO) has announced the launch of myAgios® patient support services for individuals with pyruvate kinase deficiency. This program connects patients and caregivers with dedicated Patient Support Managers, offering tailored support and educational resources. The initiative responds to the unique challenges faced by this rare disease community, aiming to improve care management. Additionally, a virtual webinar series will start on June 23, 2021, focusing on PK deficiency, enhancing community engagement and awareness.
Agios Pharmaceuticals (NASDAQ: AGIO) has submitted a New Drug Application (NDA) to the FDA for mitapivat, targeting adults with pyruvate kinase (PK) deficiency, a chronic hemolytic anemia with serious complications. This marks a pivotal step as no therapies currently exist for PK deficiency. The NDA is based on two pivotal studies, ACTIVATE and ACTIVATE-T, showcasing long-term safety and efficacy. Agios aims to address significant unmet needs in this patient community. Mitapivat is not yet approved for any use.
Agios Pharmaceuticals announced positive results from its Phase 2 study of mitapivat in adults with non-transfusion dependent α- or β-thalassemia. The primary endpoint was met, with 80% of patients showing a hemoglobin increase of ≥1.0 g/dL during Weeks 4-12. Mitapivat was well tolerated, with a safety profile consistent with previous studies. The trial involved 20 patients—5 with α-thalassemia and 15 with β-thalassemia. The company plans to initiate two Phase 3 studies in the second half of 2021, focusing on treatment options for those with thalassemia.
Agios Pharmaceuticals (NASDAQ: AGIO) announced its plan to file for regulatory approval for mitapivat, a therapy for pyruvate kinase (PK) deficiency, in the U.S. this quarter and in the EU by mid-2021. Results from the Phase 3 ACTIVATE and ACTIVATE-T studies indicate mitapivat significantly improved hemoglobin levels and reduced transfusion burdens in adults with PK deficiency. With a favorable safety profile, the findings highlight mitapivat's potential as the first disease-modifying treatment for this condition. An investor webcast is scheduled for later today.